OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access